## PhiKan 083


Cat. No.: HY-108637 CAS No.: 880813-36-5 Molecular Formula:  $C_{16}H_{18}N_{2}$ Molecular Weight: 238.33 Target: MDM-2/p53 Pathway: **Apoptosis** 

Storage: Powder -20°C 3 years

2 years

-80°C 6 months In solvent

> -20°C 1 month



**Product** Data Sheet

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (419.59 mM; Need ultrasonic) Ethanol: 100 mg/mL (419.59 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	4.1959 mL	20.9793 mL	41.9586 mL
	5 mM	0.8392 mL	4.1959 mL	8.3917 mL
	10 mM	0.4196 mL	2.0979 mL	4.1959 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (10.49 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.17 mg/mL (9.11 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.17 mg/mL (9.11 mM); Suspended solution; Need ultrasonic

## **BIOLOGICAL ACTIVITY**

Description	PhiKan 083 is a carbazole derivative, which binds to the surface cavity and stabilizes Y220C (a p53 mutant), with a $K_d$ of 167 $\mu$ M. PhiKan 083 can be used for cancer research <sup>[1]</sup> .	
IC <sub>50</sub> & Target	Kd: 167 $\mu$ M (p53-Y220C) <sup>[1]</sup> , 150 $\mu$ M (p53 <sup>Y220C</sup> , in Ln229 cells) <sup>[3]</sup>	
In Vitro	PhiKan 083 is a carbazole derivative, which binds to the surface cavity and stabilizes Y220C (a p53 mutant), with a $K_d$ of 167 $\mu$	

 $M^{[1]}$ , shows a relative binding affinity (K<sub>d</sub>) of 150  $\mu$ M for p53<sup>Y220C</sup> in Ln229 cells<sup>[3]</sup>.

PhiKan 083 slows down its thermal denaturation rate<sup>[2]</sup>.

PhiKan 083 (125 μM, 48 hours) reduces the cell viability of engineered variants of Ln229 cells<sup>[3]</sup>.

PhiKan 083 (100  $\mu$ M) in conbination with NSC 123127 (1  $\mu$ M) enhances the pro-apoptotic activity in all variants of Ln229 cells (p53<sup>wt</sup>, p53<sup>Y220C</sup>, p53<sup>G245S</sup>, p53<sup>R282W</sup>)<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay<sup>[1]</sup>

Cell Line:	Ln229, Ln229-p53-wt, Ln229-p53-Y220C, Ln229-p53-G245S, Ln229-p53-R282W cells	
Concentration:	125 μΜ	
Incubation Time:	48 hours	
Result:	Caused $\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	

## **REFERENCES**

[1]. Boeckler FM, et al. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10360-5.

[2]. Rauf SM, et al. Effect of Y220C mutation on p53 and its rescue mechanism: a computer chemistry approach. Protein J. 2013 Jan;32(1):68-74.

[3]. Paulmurugan R, et al. A protein folding molecular imaging biosensor monitors the effects of drugs that restore mutant p53 structure and its downstream function in glioblastoma cells. Oncotarget. 2018 Apr 20;9(30):21495-21511.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA